| Bioactivity | Cyclo CRLLIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains KD of 14.5 and 10.2 μM, respectively[1]. |
| Sequence | Cyclo(Cys-Arg-Leu-Leu-Ile-Phe) |
| Shortening | Cyclo(CRLLIF) |
| Formula | C36H59N9O6S |
| Molar Mass | 745.98 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ball AT, et al., Identification and Development of Cyclic Peptide Inhibitors of Hypoxia Inducible Factors 1 and 2 That Disrupt Hypoxia-Response Signaling in Cancer Cells. J Am Chem Soc. 2024 Mar 19. |